Aberdeen Group plc Grows Position in The Cooper Companies, Inc. $COO

Aberdeen Group plc lifted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 14.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 150,892 shares of the medical device company’s stock after acquiring an additional 19,550 shares during the period. Aberdeen Group plc owned 0.08% of Cooper Companies worth $10,345,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Wealth Alliance LLC increased its holdings in shares of Cooper Companies by 4.2% in the second quarter. Wealth Alliance LLC now owns 4,230 shares of the medical device company’s stock valued at $301,000 after purchasing an additional 171 shares during the period. Pacer Advisors Inc. raised its position in shares of Cooper Companies by 0.8% during the 3rd quarter. Pacer Advisors Inc. now owns 23,079 shares of the medical device company’s stock worth $1,582,000 after purchasing an additional 182 shares during the last quarter. Citizens Financial Group Inc. RI grew its stake in Cooper Companies by 2.7% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 7,181 shares of the medical device company’s stock worth $492,000 after acquiring an additional 192 shares during the period. State of Michigan Retirement System boosted its position in shares of Cooper Companies by 0.4% in the second quarter. State of Michigan Retirement System now owns 54,344 shares of the medical device company’s stock worth $3,867,000 after acquiring an additional 200 shares during the last quarter. Finally, New York Life Investment Management LLC boosted its holdings in Cooper Companies by 0.7% in the second quarter. New York Life Investment Management LLC now owns 30,019 shares of the medical device company’s stock valued at $2,136,000 after acquiring an additional 210 shares during the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Stock Performance

COO opened at $83.68 on Friday. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $92.84. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The stock has a market cap of $16.40 billion, a P/E ratio of 44.51, a P/E/G ratio of 2.38 and a beta of 1.03. The firm has a fifty day moving average price of $82.08 and a 200 day moving average price of $75.13.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.04 EPS. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. Equities research analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on COO. The Goldman Sachs Group reissued a “sell” rating and issued a $73.00 price objective on shares of Cooper Companies in a research report on Friday, January 9th. Stifel Nicolaus set a $95.00 target price on Cooper Companies and gave the company a “buy” rating in a research report on Friday, December 5th. Wells Fargo & Company boosted their price objective on Cooper Companies from $72.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, December 5th. Robert W. Baird increased their target price on shares of Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Finally, Weiss Ratings upgraded Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.77.

Insider Activity

In other Cooper Companies news, CEO Albert G. White III acquired 10,000 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was bought at an average price of $80.80 per share, for a total transaction of $808,000.00. Following the acquisition, the chief executive officer owned 236,151 shares in the company, valued at approximately $19,081,000.80. The trade was a 4.42% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Maria Rivas acquired 1,000 shares of the stock in a transaction on Thursday, December 18th. The shares were bought at an average cost of $82.13 per share, for a total transaction of $82,130.00. Following the purchase, the director directly owned 11,141 shares of the company’s stock, valued at $915,010.33. The trade was a 9.86% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 16,014 shares of company stock valued at $1,304,416 in the last ninety days. 1.98% of the stock is currently owned by corporate insiders.

Cooper Companies Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.